Nandrolone decanoate (Дека-дураболин) is considered relevant for symptomatic management across domains including wasting syndromes, osteoporosis, and specific forms of anemia. The agent may be part of symptomatic management in contexts such as osteoporosis, certain types of anemia, and for patients receiving long-term corticosteroids. This therapeutic profile supports the patient during difficult episodes by contributing to the rebuilding of structural bodily tissues during periods of severe compromise.

---

Restoring Lean Body Mass in Wasting Syndromes

This domain addresses symptoms related to systemic imbalance, specifically profound involuntary weight loss and muscle wasting (cachexia) that often cluster together in patients with advanced chronic diseases. The medication is applied in these clinical settings to promote a positive nitrogen balance. This supports patients in maintaining or improving physical resilience and assists with managing the symptoms of severe physical depletion.

---

Supporting Bone Density and Hematological Health

This treatment is commonly used to help with conditions characterized by periods of heightened physiological stress, specifically postmenopausal and senile osteoporosis, and certain cases of anemia linked to chronic kidney disease (renal insufficiency). The medication contributes to improved comfort and structural support by supporting the maintenance of bone mineral density. This supports the patient during difficult episodes by addressing the low red blood cell count and related systemic imbalance. This provides supportive relief that assists with maintaining functional stability and contributes to easing the overall symptom load.

---

Quick Fact: Symptomatic Focus in Wasting
Symptom Focus: Helps address involuntary weight loss and muscle wasting in patients with debilitating chronic conditions.
Primary Benefit: Contributes to easing symptoms related to muscle wasting and supports physical resilience during periods of severe physical depletion.

Regulatory References

1. Deca-Durabolin - NPS MedicineWise

Eligibility Map: Who Can and Cannot Use Дека-дураболин

Official regulatory documents define strict criteria for the use of Nandrolone decanoate (Дека-дураболин), based on absolute prohibitions and restrictions tied to specific patient populations.

---

Eligibility Classification	Prohibited or Restricted Populations
Absolute Contraindication	Males with known or suspected prostate or male breast carcinoma.
Absolute Contraindication	Women who are pregnant or potentially pregnant (due to fetal virilization risk).
Absolute Contraindication	Patients with nephrosis or the nephrotic phase of nephritis (severe kidney disease).
Absolute Contraindication	Individuals with known hypersensitivity to the drug or excipients (e.g., peanut/arachis oil).
Use Not Recommended	Prepubertal children and adolescents (risk of premature epiphyseal closure/stunted growth).
Use with Caution	Patients with cardiac, renal, or hepatic disease (due to risk of fluid retention).
Use with Caution	Patients with diabetes mellitus, epilepsy, or migraine (requires close monitoring).
Not Recommended	Lactating (breastfeeding) women.
Age Restriction	Children under 3 years old (due to excipient safety concern).

---

Connection to the overall eligibility profile: Regulatory documentation strictly prohibits the use of this medicine in hormone-sensitive cancers and during pregnancy. Eligibility is conditional upon careful medical assessment and close monitoring in adults with underlying cardiac, liver, or kidney conditions, where the risk of fluid retention is increased.

Interactions with other medicines and products

Interaction patterns for Nandrolone decanoate (Дека-дураболин) are documented in official regulatory sources and are primarily classified as pharmacodynamic, influencing the effects of co-administered medications.

---

Pharmacodynamic and Exposure-Modifying Interactions

Interacting Product Category	Official Interaction Statement
Oral Anticoagulants (e.g., Warfarin, Coumarin derivatives)	Nandrolone may increase the anticoagulant activities of these agents, raising the risk of bleeding. Close monitoring of prothrombin time is required, as the anticoagulant dosage may need reduction.
Antidiabetic Agents (e.g., Insulin, oral hypoglycaemics)	The drug’s metabolic effects may decrease blood glucose levels, which can reduce the required dosage of antidiabetic medication. Close monitoring of glucose levels is required for potential dosage adjustment.
Adrenocorticotropics (ACTH) or Corticosteroids	Co-administration can lead to enhanced oedema formation (fluid retention) due to an additive effect. Cautious administration is advised.
Recombinant Human Erythropoietin (rhEPO)	Concurrent use has been documented to potentially enable a reduction in the erythropoietin dose when treating anemia.

---

Interaction-Related Restrictions

Official labeling includes mandatory restrictions related to specific disease states, as the drug’s effects may compound existing risks. Nandrolone decanoate is restricted for use in patients with severe cardiac, renal, and/or hepatic dysfunction. Furthermore, use is prohibited in male patients with carcinoma of the breast or prostate.

No specific interactions requiring separation in time or dosage adjustment are explicitly documented for food, alcohol, or common supplements.

Дека-дураболин, an ester of the synthetic steroid nandrolone, functions as a prodrug, undergoing hydrolysis to the active compound, nandrolone. This active form penetrates target cells, including those in skeletal muscle and bone, and acts as an agonist at the Androgen Receptor (AR), a ligand-activated transcription factor.

Upon binding, the nandrolone-AR complex undergoes a conformational change, dimerizes, and translocates into the cell nucleus. The dimeric complex binds to specific Androgen Response Elements (AREs) on the chromosomal DNA. This DNA binding event modulates the transcription rate of various target genes. The intracellular consequence is the differential expression of genes involved in protein synthesis and nitrogen retention, driving increased net protein accretion in muscle tissue. Simultaneously, nandrolone increases the production and urinary excretion of the cytokine erythropoietin and may exert a direct stimulatory effect on hematopoietic progenitor cells within the bone marrow. These downstream cascades collectively result in a system-level modulation characterized by increased lean body mass and augmented erythropoiesis.

The use of Дека-дураболин (Nandrolone Decanoate) is governed by specific instructions focusing on the correct method of administration and dosing.

Official Administration Guidelines

Guideline	Official Instruction
Route & Method	Must be given only by deep intramuscular injection into a large muscle, such as the buttock, upper leg, or upper arm.
Dosing Schedule	The dose is highly individualized by a physician based on the specific condition and patient response. Typical adult doses for anabolic effects range from 50 mg to 100 mg or as high as 200 mg.
Frequency	Injections are administered periodically, most commonly every one to four weeks (e.g., every two or three weeks).
Dietary Requirement	Therapy is strictly adjunctive; it must be accompanied by an adequate intake of nutrients, particularly a diet rich in calories and protein, as directed by a healthcare professional.
Medical Supervision	The injection must be given only by a doctor or trained nurse.

Special Procedural Conditions

This medicine is provided as a sterile, oily solution for injection and does not require reconstitution or dilution prior to administration. The injection can be given without taking into account meals or drinks. For children aged 3 years and older, the prescribed dosage must be monitored carefully to ensure it does not interfere with growth and sexual development. If a patient misses a scheduled injection, they must contact their doctor or nurse as soon as possible for a new appointment; a double dose should not be injected to make up for a forgotten dose.

Research evidence / Overview of Studies for Дека-дураболин

This overview summarizes the structure and reported observations from clinical research regarding Nandrolone decanoate (Дека-дураболин). This section describes what was studied and what patterns were observed in patient groups, without giving any clinical advice or making personal predictions about outcomes.

---

Evidence for Use in Managing Anemia Related to Chronic Kidney Disease

The medication was studied for its role in managing outcomes related to systemic imbalance, specifically anemia related to chronic kidney disease (CKD). The foundational evidence relies on historical controlled clinical trials where research examined how hematological markers like hemoglobin were monitored. Historical trials reported how symptoms evolved in the observed populations over defined time intervals of three to six months. However, the evidence quality varies across studies as much of the supporting research is older, and comparative evidence is lacking.

---

Evidence for Use in Addressing Wasting Syndromes

Research explored the use of this medication in conditions marked by functional limitations, such as involuntary weight loss and muscle wasting (cachexia). Studies included short-term randomized controlled trials (RCTs) where investigators examined objective outcomes related to body composition, specifically measuring changes in Lean Body Mass (LBM). The research base for this domain was observed in some studies to align with a Moderate level of evidence. A major limitation is that follow-up durations were limited, often covering only 12 to 16 weeks, meaning there is limited information for long-term outcomes.

---

Evidence for Use in Treating Osteoporosis

Research has explored the use of this medication in conditions marked by functional limitations, such as postmenopausal and senile osteoporosis. The evidence base includes systematic reviews and meta-analyses that aggregate data from multiple clinical trials, where studies examined objective outcomes related to skeletal structure, including changes in Bone Mineral Density (BMD) and vertebral fractures. The evidence base for this indication was observed in some studies to align with a High evidence classification. Nevertheless, sample sizes were modest in several key studies, and evidence quality varies across studies regarding the consistency of BMD gains.

---

Long-Term Studies and Follow-up Durations

Research has focused primarily on studies observing responses over defined time intervals that are typically short-term to intermediate for most conditions. Consequently, long-term effects are not fully established across all indications. There is limited information for long-term outcomes available to fully characterize the durability of the measured outcomes after treatment is discontinued.

---

Evidence in Special Populations

Research examined how certain patient subgroups were monitored, including elderly women with osteoporosis and distinct cohorts of both men and women with HIV-associated wasting. However, the results apply only to the populations studied. Data for certain groups, such as children, remain insufficient or limited, reflecting a focused research history.

---

What is Still Uncertain About Дека-дураболин Research

The research provides insight into short-term changes, but several gaps and limitations persist. Evidence quality varies across studies, and follow-up durations were limited, making it challenging to draw conclusions about long-term patient outcomes. This means research highlights what is known — and what is still uncertain, reflecting the specific conditions under which studies were conducted.

Common questions about Дека-дураболин (FAQ)

Q: What is Deca-Durabolin used for, besides its main indication?

Regulatory documents primarily indicate its use for managing anemia related to chronic kidney disease. Historical uses and research have also involved its role in managing osteoporosis and certain wasting syndromes. This focus reflects the drug's core function of promoting tissue growth and protein buildup.

Q: Does this drug have other names I can search for?

Yes, this medication is also widely known by the trade name Deca-Durabolin in some regions and is the name most commonly associated with the active compound, Nandrolone Decanoate. All official names refer to the same regulated substance.

Q: How long does it usually take for Deca-Durabolin to start working?

The drug is administered as an oily solution designed for a slow, sustained release into the body. Official pharmacokinetic data indicate that the peak concentration in the blood is typically reached between 30 to 72 hours after the injection. However, the time required to observe a therapeutic effect can vary based on the condition being addressed.

Q: How long does the drug remain in the body after the last injection?

The drug is formulated with a long-acting ester (decanoate), allowing it to be released slowly over an extended period. Official pharmacokinetic studies report that the drug's half-life is approximately 7 to 12 days. This extended-release feature is why it is suitable for periodic administration.

Q: Are there other medications similar to Deca-Durabolin in effect?

Yes, the drug belongs to the class of Anabolic-Androgenic Steroids (AAS), which are hormonal agents. This class includes other compounds that function similarly by acting on the androgen receptor to promote tissue growth and protein synthesis. These drugs are all structurally related to the male sex hormone testosterone.

Q: How does Deca-Durabolin differ from testosterone?

The drug is a synthetic derivative of testosterone. Official pharmacological information indicates its chemical structure is modified to enhance its anabolic activity (tissue building) while reducing its androgenic activity (masculinizing effects). This modification results in a different balance of effects compared to the natural hormone.

Q: Is it true that Deca-Durabolin can cause joint problems?

Regulatory documents describing the use and withdrawal of anabolic steroids sometimes include reports of general muscle or joint pain as a possible symptom. This effect is not universally documented but is observed in some reports related to the use or discontinuation of this drug class.

Q: What changes in mood or psychological effects might occur?

Official product labeling documents potential central nervous system (CNS) adverse reactions. These reported effects include feelings of excitation and habituation (dependence). Other documented CNS effects are insomnia (sleeplessness) and depression.

Q: Why do some people refer to 'Deca-dick'?

This term is an unofficial reference to the documented effects that anabolic steroids can have on the male genitourinary system. Official information lists potential side effects such as impotence and erectile dysfunction (ED). These effects are related to the drug's influence on the body's natural hormone production.

Q: Can women safely use Deca-Durabolin?

The drug is strictly contraindicated (prohibited) for use during pregnancy due to the risk of fetal harm. Non-pregnant women are monitored for signs of virilization (masculinizing effects), such as voice changes and hirsutism. The labeling notes that these effects may not be fully reversible.

Q: Can Deca-Durabolin interact with blood pressure medications?

While specific interactions with all blood pressure medications are not universally listed, the drug's known potential to cause edema (fluid retention) is a major concern. This fluid retention can worsen underlying conditions like congestive heart failure. Therefore, caution is generally observed in patients with pre-existing cardiac or renal disease.

Q: Does Deca-Durabolin affect cholesterol levels?

Yes, as an anabolic-androgenic steroid, the drug is known to affect the body's lipid profile. Official data indicates that use can lead to documented alterations in cholesterol levels, commonly including a decrease in HDL (high-density lipoprotein) and an increase in LDL (low-density lipoprotein).

Q: How does Deca-Durabolin affect sleep?

Official regulatory documents list insomnia (sleeplessness) as a documented central nervous system (CNS) side effect. Patients should report any significant changes in sleep patterns to their prescribing healthcare provider.

Q: Is it true that Deca-Durabolin can help with anemia?

The drug is officially indicated for the management of the anemia of renal insufficiency, which is anemia related to kidney disease. Studies and official information indicate observations of its ability to increase hemoglobin and red cell mass, supporting the treatment of this condition.

Q: What diseases were the focus of early research on Deca-Durabolin?

Beyond the primary indication for chronic kidney disease-related anemia, historical regulatory and research efforts focused on several wasting conditions. Studies concentrated on its potential role in managing osteoporosis and various wasting syndromes that cause loss of muscle and bone mass.

Q: What are the long-term effects of using Deca-Durabolin, according to studies?

Serious adverse reactions have been documented in association with long-term use of anabolic steroids. These include the potential for hepatic tumors (liver neoplasms) and a rare, but serious, condition called peliosis hepatis, which involves blood-filled cysts in the liver.

Q: How often should I have blood tests while using the drug?

The official product labeling emphasizes the necessity of frequent monitoring while receiving treatment. This includes regular checks of hemoglobin, hematocrit, liver function, and lipid levels, but does not state a universal frequency for monitoring.

Q: What should be done if a Deca-Durabolin injection was given incorrectly?

Regulatory guidance strictly requires that the injection be given only by a doctor or trained nurse using a deep intramuscular route. Concerns about an improperly administered injection should be communicated immediately to the prescribing healthcare professional.

Q: Why is Deca-Durabolin banned by some sports organizations?

The drug is classified as an Anabolic-Androgenic Steroid (AAS). Because of its known performance-enhancing properties, it is listed by major organizations, such as the World Anti-Doping Agency (WADA), as a prohibited substance in competitive sports.

Q: What side effects are considered normal at the beginning of treatment?

According to official documentation, the most commonly reported adverse reactions associated with this drug class are fluid retention (edema) and acne. Patients should discuss expected side effects and any concerning reactions with their healthcare team.

Q: How does the drug affect the cardiovascular system?

Official product information notes that anabolic steroids can precipitate cardiovascular effects. Specifically, edema (fluid retention) has occurred during therapy, which can be problematic for individuals with pre-existing heart conditions, such as congestive heart failure.

Q: What documents or regulatory bodies have approved Deca-Durabolin?

The drug is subject to approval and regulation by governmental agencies in every country where it is legally marketed. Examples of these regulatory bodies include the U.S. Food and Drug Administration (FDA) and Health Canada in their respective jurisdictions.

Q: Why is the drug often mentioned in the context of hormonal therapy?

The medication is officially classified as an Anabolic-Androgenic Steroid, which is a class of hormonal agents. This classification means it functions similarly to the male sex hormone testosterone within the body, naturally placing it in the context of therapies that modulate hormone levels.

Q: How does the drug affect sexual function?

Official labeling documents several potential effects on the genitourinary system. These side effects include changes in libido (sex drive), impotence, and, in postpubertal men, inhibition of testicular function. Rare side effects like chronic priapism (prolonged, painful erection) have also been reported.

Q: What warnings does the manufacturer provide regarding the use of the drug?

Major official warnings highlight several risks: the potential for hepatic tumors with long-term use, the risk of developing virilization in women, and the risk of fluid retention which can worsen heart or kidney problems. Close monitoring is a necessary part of the treatment protocol for all patients, especially children.

Q: Is Deca-Durabolin associated with baldness?

As an anabolic-androgenic steroid, the drug can cause androgenic side effects. Official documentation reports that these effects in women can include male pattern baldness (androgenic alopecia), along with unusual hair growth on the face and body.

Q: Can Deca-Durabolin be used for weight gain?

The general purpose of the drug is to promote tissue growth and anabolism. It is officially used as supportive care for patients experiencing significant involuntary weight loss or muscle wasting by promoting a positive nitrogen balance in the body.

Q: What happens if I suddenly stop using Deca-Durabolin?

Because the medication can alter the body's natural production of hormones, stopping abruptly can lead to symptoms of hormonal imbalance. Reported effects related to sudden cessation include depression, fatigue, loss of libido, and impotence in men.

Q: Can Deca-Durabolin affect laboratory test results?

Yes, official product information states that the drug may interfere with the results of several lab tests. Reported effects include possible increases in levels of creatinine, lipids, calcium, and liver enzymes. It may also decrease certain thyroid function test values.

Q: What symptoms require immediate contact with a doctor during treatment?

Symptoms that the official labeling recommends reporting immediately include developing hoarseness, persistent ankle swelling (edema), feelings of nausea or vomiting, and changes in skin color (jaundice) or menstrual periods.

Q: How effective is Deca-Durabolin treatment in clinical settings?

The drug is officially indicated for its specified uses, such as managing anemia of renal insufficiency. In this clinical context, studies have observed increases in hemoglobin and red cell mass in the context of its indicated use.

Q: Does Deca-Durabolin have a potential for abuse?

Yes, the drug is officially recognized for its potential for abuse. It is classified as a Schedule III controlled substance under the Anabolic Steroids Control Act in the United States, which indicates a known potential for physical and psychological dependence.

How to Store and Dispose of Nandrolone Decanoate Injection

The storage and disposal requirements for Nandrolone Decanoate injection are strictly defined by regulatory guidance to ensure product stability and safety.

Storage and Protection Requirements
Temperature: Store at Controlled Room Temperature (20 C to 25 C).
Environment: Must be kept in the original, tightly closed container and stored away from excess heat and moisture; do not store in the bathroom.
Child Safety: Keep the medicine out of the sight and reach of children and secure it in an up-and-away location.

For disposal, the preferred method is a drug take-back program. If one is unavailable, the medication may be disposed of in household trash by mixing it with an undesirable substance (such as dirt) and sealing it in a container. The product is not listed for disposal by flushing.